Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

AbbVie is the lead sponsor of 232 current clinical trials in our USA, Spain, Japan, Israel, France, Germany, Canada, Italy, Australia, China, UK, Taiwan, South Korea, Belgium, Poland, Czechia, Netherlands, Austria, Portugal, Sweden, Turkey, Mexico, Brazil, Denmark, Switzerland, Ireland, Norway, Singapore, Egypt, India and EU (CTIS) registers. 111 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Upadacitinib, Telisotuzumab Adizutecan and Venetoclax. The most-studied condition is Crohn's Disease.

Company profiles on this site (news, sites, medicines, approvals): AbbVie Ireland (IE) →AbbVie (US) →

ClinicalTrials.gov trials by status

Recruiting11149%
Not yet open10%
Active, closed10748%
By invitation63%

Trials by phase

Phase 35826%
Phase 15223%
Phase 24721%
Observational4520%
Phase 1/2104%
Phase 2/3104%
Phase 431%

Clinical trials sponsored by AbbVie

225 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784 · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer Drugs: Bevacizumab, Carboplatin, IMGN151	Phase 2	Recruiting	2025-07	USA, Japan, Israel
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations NCT06892522 · Multiple Myeloma Drugs: Carfilzomib, Daratumumab, Dexamethasone	Phase 1/2	Recruiting	2025-06	UK, USA, Norway, Japan, Australia, Israel
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium NCT07382440 · ClinicalTrials.gov ↗ · Parkinson's Disease	Observational	Recruiting	2026-03	Belgium
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206 · Colorectal Cancer Drugs: Bevacizumab, Telisotuzumab Adizutecan, Trifluridine/Tipiracil	Phase 3	Recruiting	2026-05	USA, China, Germany, Spain, Belgium, Portugal, Japan, South Korea, Taiwan, Egypt
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07365241 · Small Cell Lung Cancer Drugs: ABBV-706, Amrubicin, Lurbinectedin	Phase 3	Recruiting	2026-07	USA, Germany, France, Spain, Belgium, Switzerland, Austria, Brazil, Japan, Egypt
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187 · Non-Small Cell Lung Cancer Drugs: Osimertinib, Telisotuzumab Adizutecan	Phase 2/3	Recruiting	2025-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Portugal, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease NCT07023289 · Colorectal Cancer Drug: Telisotuzumab Adizutecan	Phase 2	Recruiting	2025-09	USA, China, Spain, Italy, Belgium, Denmark, Japan, South Korea, Taiwan
Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease NCT06937034 · ClinicalTrials.gov ↗ · Parkinson's Disease	Observational	Recruiting	2025-04	Netherlands, Sweden, Austria
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma NCT06830759 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma, Follicular Lymphoma	Observational	Recruiting	2025-03	UK, Spain, Italy, Belgium, Austria, Portugal, Canada, Mexico, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) NCT06953960 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Daratumumab, Dexamethasone, Etentamig	Phase 1/2	Recruiting	2025-07	UK, USA, Germany, France, Italy, Belgium, Sweden, Poland, Portugal, Japan, Australia, Israel
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer NCT07155174 · Small Cell Lung Cancer Drugs: ABBV-706, Atezolizumab, Carboplatin	Phase 2	Recruiting	2025-11	USA, China, Germany, Spain, Italy, Belgium, Poland, Turkey, Japan, South Korea, Taiwan, Israel
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease NCT06548542 · ClinicalTrials.gov ↗ · Crohn's Disease Drugs: Lutikizumab, Risankizumab, Trosunilimab	Phase 2	Recruiting	2024-09	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, South Korea, Taiwan, Singapore, Israel
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drugs: Dupilumab, Upadacitinib	Phase 3	Recruiting	2024-08	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis NCT07136116 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Observational	Recruiting	2025-10	Japan
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder NCT07071532 · Bipolar Disorder Drugs: ABBV-932, Itraconazole	Phase 1	Recruiting	2026-08	USA
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) NCT07409246 · Multiple Myeloma	Phase 1	Recruiting	2026-02	USA, China, Japan, Israel
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis NCT06764693 · ClinicalTrials.gov ↗ · Psoriatic Arthritis	Observational	Recruiting	2025-01	Ireland, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Taiwan, Israel
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT04928846 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drugs: Docetaxel, Telisotuzumab vedotin	Phase 3	Recruiting	2022-03	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer NCT07059845 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Bevacizumab, Carboplatin, Mirvetuximab Soravtansine	Phase 2	Recruiting	2025-11	USA, France, Spain, Belgium, Denmark, Czechia, South Korea, Australia
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease NCT06332534 · Crohn's Disease Drug: Upadacitinib	Phase 3	Recruiting	2024-08	UK, USA, China, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) NCT07007065 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration Drug: Surabgene Lomparvovec	Phase 3	Recruiting	2025-11	UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Portugal, Canada, Israel
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa NCT07136467 · ClinicalTrials.gov ↗ · Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa	Observational	Recruiting	2025-09	UK, Germany, France, Spain, Italy, Switzerland, Czechia, Canada, Japan, South Korea, Taiwan
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. NCT05609630 · ClinicalTrials.gov ↗ · Juvenile Idiopathic Arthritis Drugs: Tocilizumab, Upadacitinib	Phase 3	Recruiting	2023-10	UK, USA, China, Germany, Spain, Italy, Netherlands, Sweden, Austria, Turkey, Brazil, Mexico, Japan, Taiwan, Australia
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab NCT06389136 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drugs: Dupilumab, Upadacitinib	Phase 3	Recruiting	2024-06	USA, Spain, Italy, Canada, Japan, South Korea, Israel
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06568939 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Telisotuzumab vedotin	Phase 2	Recruiting	2025-01	USA, China, Brazil, Japan, Singapore, Israel
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) NCT07581002 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Azacitidine, Pivekimab Sunirine, Venetoclax	Phase 2/3	Recruiting	2026-06	USA, China, France, Spain, Austria, South Korea, Taiwan, Israel
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium NCT06581042 · ClinicalTrials.gov ↗ · Ulcerative Colitis, Crohn's Disease	Observational	Recruiting	2024-09	Belgium
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years NCT06810505 · ClinicalTrials.gov ↗ · Chronic Migraine Drug: Atogepant	Phase 3	Recruiting	2025-02	UK, USA, Italy, Netherlands, Denmark, Poland, Portugal, Canada, Japan
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India NCT07044687 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Azacitidine, Venetoclax	Phase 4	Recruiting	2025-07	India
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine NCT06602479 · ClinicalTrials.gov ↗ · Migraine	Phase 2	Recruiting	2024-10	USA, Germany, Spain, Italy, Denmark, Poland, Czechia
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06896916 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Etentamig, Iberdomide	Phase 1	Recruiting	2025-08	USA, France, Netherlands, Norway, Canada, Japan, Australia
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata NCT06012240 · ClinicalTrials.gov ↗ · Alopecia Areata Drug: Upadacitinib	Phase 3	Recruiting	2023-10	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102 · ClinicalTrials.gov ↗ · Non-Squamous Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Osimertinib	Phase 2/3	Recruiting	2025-08	USA, China, Spain, Italy, Belgium, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease NCT05995353 · ClinicalTrials.gov ↗ · Crohn's Disease Drug: Risankizumab	Phase 3	Recruiting	2023-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Czechia, Turkey, Canada, Japan, South Korea, Taiwan, Israel
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers NCT07769502 · ClinicalTrials.gov ↗ · Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma Drugs: Gemcitabine, Nab-paclitaxel, Telisotuzumab Adizutecan	Phase 2	Recruiting	2026-08	China, Japan, Taiwan, Israel
A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy NCT07407062 · ClinicalTrials.gov ↗ · Cancer - Ovarian	Observational	Recruiting	2026-06	Italy
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries NCT07539844 · ClinicalTrials.gov ↗ · Ovarian Cancer	Observational	Recruiting	2026-07	Canada, Brazil, Mexico
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer NCT07278336 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Bevacizumab, Carboplatin	Phase 1	Recruiting	2025-11	USA, China, Spain, Portugal, Japan, Taiwan, Australia, Israel
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT05650632 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Etentamig	Phase 1	Recruiting	2023-03	UK, USA, France, Spain, Denmark, Canada, Israel
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants NCT06575192 · Breast Reconstruction	Phase 3	Recruiting	2024-11	USA
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis NCT06865105 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drugs: Lutikizumab, Risankizumab	Phase 2	Recruiting	2025-04	USA, France, Poland, Czechia, Canada
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor NCT07673107 · Upper Limb Essential Tremor Drug: AGN-151607-DP	Phase 2	Recruiting	2026-06	USA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT06428019 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia Drugs: Acalabrutinib, Obinutuzumab, Venetoclax	Phase 3	Recruiting	2024-08	UK, USA, China, France, Spain, Taiwan, Australia
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting NCT07421258 · ClinicalTrials.gov ↗ · Crohn's Disease, Ulcerative Colitis	Observational	Recruiting	2026-02	China, France
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT07039110 · ClinicalTrials.gov ↗ · Plaque Psoriasis	Observational	Recruiting	2025-09	Germany, France, Spain, Italy, Czechia, Canada, Japan
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis NCT07230288 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis	Phase 2	Recruiting	2026-01	UK, USA, China, Germany, France, Spain, Poland, Portugal, Turkey, Canada, Japan, South Korea, Taiwan, Australia
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease NCT07227896 · ClinicalTrials.gov ↗ · Parkinson's Disease	Observational	Recruiting	2026-08	UK, USA, Israel
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) NCT06858813 · ClinicalTrials.gov ↗ · Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer Drug: Lenvatinib	Phase 1	Recruiting	2025-04	USA, China, Spain, Japan, Taiwan, Israel
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988 · ClinicalTrials.gov ↗ · Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers Drugs: MIRV, Mirvetuximab Soravtansine	Phase 2	Recruiting	2025-05	UK, USA, France, Spain, Belgium, Poland, South Korea, Australia
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer NCT06820463 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Bevacizumab, Fluorouracil, Leucovorin	Phase 2	Recruiting	2025-04	UK, USA, France, Spain, Austria, Czechia, Canada, Brazil, Japan, Taiwan, Australia, Israel
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis NCT07071519 · ClinicalTrials.gov ↗ · Ulcerative Colitis Drug: Risankizumab	Phase 3	Recruiting	2025-07	UK, USA, China, Germany, Spain, Italy, Belgium, Sweden, Canada, Brazil, Japan, South Korea, Taiwan
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623 · ClinicalTrials.gov ↗ · Non Small Cell Lung Carcinoma Drugs: Budigalimab, Carboplatin, Cisplatin	Phase 1/2	Recruiting	2025-03	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Japan, Taiwan, Australia
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma NCT07490301 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma, PDAC Drugs: Fluorouracil, Irinotecan, Oxaliplatin	Phase 2/3	Recruiting	2026-04	UK, USA, China, Japan, South Korea, Taiwan, Australia, Israel
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis NCT06972446 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Drug: Lutikizumab	Phase 2	Recruiting	2025-06	USA, Germany, Spain, Poland, Czechia, Canada, South Korea, Taiwan
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) NCT04895436 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL) Drugs: Obinutuzumab, Venetoclax	Phase 2	Recruiting	2022-03	UK, USA, Germany, Spain, Italy, Austria, Brazil, Australia, Israel
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume NCT06734351 · Mid Face Volume Deficit	Phase 3	Recruiting	2024-12	USA
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan NCT07196644 · ClinicalTrials.gov ↗ · Solid Tumors Harboring MET Amplification Drug: Telisotuzumab Adizutecan	Phase 2	Recruiting	2025-12	USA, Spain, Japan, South Korea, Israel
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting NCT03342144 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL)	Observational	Recruiting	2017-12	Germany, Switzerland, Austria
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07160179 · Geographic Atrophy, Age-Related Macular Degeneration	Phase 1/2	Recruiting	2025-08	USA
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Daratumumab, Dexamethasone, Etentamig	Phase 2/3	Recruiting	2026-01	USA, France, Spain, Japan
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) NCT07607964 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Rheumatoid Arthritis	Phase 1	Recruiting	2026-05	USA, Japan
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Budigalimab, Carboplatin, Cisplatin	Phase 2/3	Recruiting	2024-04	USA, France, Spain, Netherlands, Belgium, Turkey, Japan, Taiwan, Australia, Israel
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT07306832 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drug: Pivekimab Sunirine	Phase 1	Recruiting	2026-05	UK, USA, France, Italy, South Korea, Taiwan, Australia
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine NCT05711394 · ClinicalTrials.gov ↗ · Episodic Migraine Drug: Atogepant	Phase 3	Recruiting	2023-05	UK, USA, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Canada, Japan, Israel
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata NCT07772492 · Severe Alopecia Areata Drug: Upadacitinib	Phase 3	Recruiting	2026-08	USA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 NCT06084481 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Drugs: Bevacizumab, Itraconazole, Telisotuzumab Adizutecan	Phase 1	Recruiting	2023-11	USA, China, Spain, Japan, South Korea, Taiwan, Australia, Israel
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan NCT06023030 · ClinicalTrials.gov ↗ · Crohn's Disease	Observational	Recruiting	2023-07	Japan
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING NCT06712628 · ClinicalTrials.gov ↗ · Moderate to Severe Rheumatoid Arthritis	Observational	Recruiting	2024-11	Germany
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA) NCT06977724 · ClinicalTrials.gov ↗ · Dry Eye Syndrome, Systemic Lupus Erythematosus Drug: ABBV-319	Phase 1	Recruiting	2025-08	USA, France, Netherlands
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine NCT06603558 · ClinicalTrials.gov ↗ · Chronic Migraine, Episodic Migraine, Migraine Drug: Atogepant	Observational	Recruiting	2024-09	South Korea
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion NCT06158854 · ClinicalTrials.gov ↗ · Immunoglobulin Light Chain (AL) Amyloidosis Drug: Etentamig	Phase 1/2	Recruiting	2024-04	USA, France, Italy, Japan, Australia
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan NCT05005403 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer Drugs: Bevacizumab, Budigalimab, Telisotuzumab Adizutecan	Phase 1	Recruiting	2021-11	USA, Canada, Japan, South Korea, Taiwan, Israel
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants NCT07673120 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Recruiting	2026-06	USA
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis NCT07697456 · ClinicalTrials.gov ↗ · Crohn's Disease, Ulcerative Colitis Drugs: ABBV-701, Risankizumab, Trosunilimab	Phase 2	Recruiting	2026-07	USA, China, Taiwan
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab NCT06100744 · ClinicalTrials.gov ↗ · Juvenile Psoriatic Arthritis Drugs: Adalimumab, Risankizumab, Skyrizi	Phase 3	Recruiting	2024-07	UK, USA, Germany, France, Spain, Italy, Poland, Canada, Australia
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors NCT07241039 · ClinicalTrials.gov ↗ · Advanced Squamous Tumors Drug: Budigalimab	Phase 1	Recruiting	2025-11	USA, Canada, Japan, Israel
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy NCT05158894 · ClinicalTrials.gov ↗ · Migraine	Observational	Recruiting	2023-01	USA, Canada
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis NCT06764706 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Observational	Recruiting	2025-02	Germany
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants NCT07570147 · ClinicalTrials.gov ↗ · Healthy Volunteer	Phase 1	Recruiting	2026-05	USA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants NCT06345339 · ClinicalTrials.gov ↗ · Hypothyroidism Drug: Levothyroxine	Phase 2/3	Recruiting	2024-04	USA
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data NCT07419347 · ClinicalTrials.gov ↗ · Hepatitis C Virus (HCV)	Observational	Recruiting	2026-02	Canada
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS) NCT06916507 · ClinicalTrials.gov ↗ · Parkinson's Disease	Observational	Recruiting	2025-05	Germany
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder NCT06846320 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder (GAD) Drug: ABBV-932	Phase 2	Recruiting	2025-04	USA
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. NCT04777357 · ClinicalTrials.gov ↗ · Depression, Bipolar I Disorder Drug: Cariprazine	Phase 3	Recruiting	2021-04	USA
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting NCT07073079 · ClinicalTrials.gov ↗ · Crohn's Disease	Observational	Recruiting	2025-07	Italy
A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa NCT07284342 · ClinicalTrials.gov ↗ · Advanced Parkinson's Disease	Observational	Recruiting	2025-11	Spain
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications NCT04846959 · ClinicalTrials.gov ↗ · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment Drug: Risankizumab	Observational	Recruiting	2021-07	USA
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma NCT06822738 · ClinicalTrials.gov ↗ · Primary Open Angle Glaucoma	Phase 3	Recruiting	2025-02	USA
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease NCT06965374 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2025-06	Italy
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults. NCT07306754 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Recruiting	2025-12	USA
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines NCT07756580 · ClinicalTrials.gov ↗ · Glabellar Lines Drugs: AGN-151586, Botox	Phase 1	Recruiting	2026-08	USA
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants NCT07466550 · ClinicalTrials.gov ↗ · Healthy Volunteer Drug: Risankizumab	Phase 1	Recruiting	2026-06	USA
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants NCT07736638 · ClinicalTrials.gov ↗ · Healthy Volunteer	Phase 1	Recruiting	2026-07	USA
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) NCT05125302 · ClinicalTrials.gov ↗ · Migraine Drug: Ubrogepant	Phase 3	Recruiting	2022-01	USA
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease NCT07599670 · ClinicalTrials.gov ↗ · Alzheimer's Disease	Phase 1/2	Recruiting	2026-05	USA, China
Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants NCT07680686 · ClinicalTrials.gov ↗ · Healthy Volunteer Drug: Ubrogepant	Phase 1	Recruiting	2026-07	USA
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants NCT07730554 · ClinicalTrials.gov ↗ · Forehead Lines Drug: AGN-151586	Phase 2	Recruiting	2026-07	USA
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema NCT07592273 · ClinicalTrials.gov ↗ · Diabetic Retinopathy Drug: Surabgene Lomparvovec	Phase 2/3	Recruiting	2026-06	USA
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults NCT07794878 · ClinicalTrials.gov ↗ · Nasolabial Folds	Phase 3	Recruiting	2026-08	China
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities NCT07752979 · ClinicalTrials.gov ↗ · Obesity, Overweight Drug: ABBV-295	Phase 2	Recruiting	2026-08	USA

Showing the 100 most recently updated of 225 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

AbbVie in the EU trials register (CTIS)

7 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with AbbVie as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD) 2026-526282-25-00 · Immune System Diseases	Phase 1	Authorised	Germany
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy 2025-523724-47-00 · Neoplasms Drugs: Azacitidine, Pivekimab Sunirine, Venetoclax	Phase 3	Ongoing	France, Austria, Spain
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) 2025-523819-11-00 · Neoplasms Drugs: ABBV-706, Topotecan	Phase 3	Ongoing	Italy, Greece, Spain + 4 more
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma 2025-525105-20-00 · Neoplasms Drug: Etentamig	Phase 1	Ongoing	Germany, Poland, Czechia + 6 more
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 2025-522563-15-00 · Neoplasms Drugs: Calcium folinate, Fluorouracil, Irinotecan	Phase 3	Authorised	Portugal, Spain, France + 3 more
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis 2025-523127-21-00 · CTIS ↗ · Immune System Diseases	Phase 1	Ongoing	Belgium, Netherlands, Spain + 2 more
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML). 2024-520125-36-00 · CTIS ↗ · Neoplasms Drug: Pivekimab Sunirine	Phase 1	Ongoing	Spain, Hungary, Czechia + 3 more

Drugs in AbbVie trials

94 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 54 more in the trial list above.

Conditions in AbbVie trials

153 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in USA	172	86
Clinical trials in Spain	103	40
Clinical trials in Japan	96	40
Clinical trials in Israel	86	32
Clinical trials in France	82	31
Clinical trials in Germany	79	26
Clinical trials in Canada	78	28
Clinical trials in Italy	77	30
Clinical trials in Australia	72	25
Clinical trials in China	69	29
Clinical trials in UK	68	27
Clinical trials in Taiwan	66	30
Clinical trials in South Korea	64	25
Clinical trials in Belgium	56	23
Clinical trials in Poland	48	19
Clinical trials in Czechia	37	12
Clinical trials in Netherlands	36	12
Clinical trials in Austria	35	14
Clinical trials in Portugal	31	13
Clinical trials in Sweden	31	8
Clinical trials in Turkey	30	10
Clinical trials in Mexico	27	5
Clinical trials in Brazil	26	11
Clinical trials in Denmark	25	8
Clinical trials in Switzerland	21	5
Clinical trials in Ireland	20	2
Clinical trials in Norway	12	3
Clinical trials in Singapore	12	4
Clinical trials in Egypt	5	2
Clinical trials in India	1	1
EU register (CTIS)	7	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Crohn's Disease

Sponsor	Trials
Takeda	15
Janssen-Cilag	2
Asan Medical Center	2
Jiangsu Topcel-KH Pharmaceutical	1
Xiang Gao	1
Esbjerg Hospital - University Hospital of Southern Denmark	1

Sponsors with the most current trials registered for this condition.

Questions about AbbVie trials

How many clinical trials does AbbVie sponsor?

AbbVie is the lead sponsor of 225 current trials on ClinicalTrials.gov in our USA, Spain, Japan, Israel, France, Germany, Canada, Italy, Australia, China, UK, Taiwan, South Korea, Belgium, Poland, Czechia, Netherlands, Austria, Portugal, Sweden, Turkey, Mexico, Brazil, Denmark, Switzerland, Ireland, Norway, Singapore, Egypt and India registers, and 7 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are AbbVie trials recruiting?

Yes. 111 of its 225 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is AbbVie testing?

Its current trials name 94 drugs and biologicals as interventions. The most frequent are Upadacitinib (19), Telisotuzumab Adizutecan (17), Venetoclax (16), Risankizumab (15) and Budigalimab (13). The number in brackets is how many of its trials name each drug.

Does AbbVie have clinical trials in Ireland?

Yes. 20 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

AbbVie clinical trials